BUSINESS

Kimberly-Clark prepares asset sales to win EU nod for Kenvue deal, sources say

PUBLISHED Sep 14, 2026, 4:00 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 39

Center 100%

Sources: 39

Kimberly-Clark is preparing asset divestments and regulatory concessions to address European Union antitrust concerns regarding its multi-billion-dollar acquisition of Tylenol maker Kenvue. Sources familiar with the matter report that the European Commission is set to formally notify the companies of its preliminary competition concerns. This regulatory notification will determine whether Kimberly-Clark submits formal remedies before the preliminary review window closes on September 29, or moves into an extended four-month in-depth investigation. Investor response to the potential remedies lifted shares for both corporations in early trading. The transaction previously secured conditional approvals in Australia and South Africa, which required targeted divestitures of overlapping personal care lines. The strategic merger comes amid a challenging macroeconomic environment characterized by heightened consumer price-consciousness and margin pressures across the global consumer goods sector. Both corporations have not publicly commented on the ongoing Brussels regulatory discussions.

By Ayesha A. | JQJO News

Timeline of Events

On Nov 3, 2025 Kimberly-Clark announced plans to acquire Kenvue for forty-eight billion dollars.
On Jan 15, 2026 Shareholders from both corporations overwhelmingly approved the planned merger transactions.
On Feb 10, 2026 US antitrust waiting periods expired under Hart-Scott-Rodino regulatory provisions.
On Jun 20, 2026 The European Commission cleared the transaction under foreign subsidy regulations.
On Aug 26, 2026 Kimberly-Clark formally filed antitrust paperwork with European Union regulators.
On Aug 28, 2026 South African antitrust authorities granted conditional approval for the transaction.
On Sep 7, 2026 Australian competition regulators cleared the deal with mandatory asset divestitures.
On Sep 14, 2026 Sources reported Kimberly-Clark is preparing EU antitrust concessions and asset sales.
On Sep 29, 2026 European regulators face a preliminary review deadline for the transaction.
On Dec 31, 2026 Corporate executives target final transaction closure during late fourth quarter.

News Intelligence

Immediate US impact: Immediate US stock values rose following expected regulatory progress news.
Possible long-term US impact: Long-term market consolidation could reshape domestic personal care product pricing.
Most affected groups: Consumer goods corporations, retail investors, and personal care sector stakeholders.
Reader priority: Prioritize financial wire reports and official corporate investor relation filings.

Media Bias

Articles Published:: 39
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 39

Explain Framing

Left: Corporate consolidation threatens market competition and demands rigorous regulatory oversight. Center: Market forces drive corporate mergers requiring standard regulatory antitrust compliance. Right: Mergers enhance economic efficiency while regulatory hurdles delay business growth.